Xilio Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $166.1M | $177.0M |
| Jun 2022 | — | $144.2M | $159.4M |
| Sep 2022 | — | $126.3M | $139.1M |
| Dec 2022 | — | $105.6M | $120.4M |
| Mar 2023 | — | $84.8M | $93.3M |
| Jun 2023 | — | $67.4M | $75.4M |
| Sep 2023 | — | $52.5M | $59.8M |
| Dec 2023 | — | $36.8M | $44.7M |
| Mar 2024 | — | $25.8M | $34.0M |
| Jun 2024 | — | $33.4M | $74.9M |
| Sep 2024 | — | $21.0M | $61.3M |
| Dec 2024 | — | $17.6M | $55.3M |
| Mar 2025 | — | $10.7M | $89.1M |
| Jun 2025 | — | $7.1M | $121.6M |
| Sep 2025 | — | $-8.1M | $103.8M |
| Dec 2025 | — | $35.3M | $137.5M |
| Mar 2026 | — | $72.5M | $150.3M |
| Jun 2026 | — | $72.3M | $136.0M |